Resources Repository
-
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Decision Analysis | Global | Policy/Regulation | Costing Methods | Health Outcomes | Evidence Synthesis | Health/Medicine | Graduate | Doctoral | Professional -
Working PaperPublication 2024Economic Evaluation Primer
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence …
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence needed to support sound policy decisions. In low- and middle-income countries, where resources are especially scarce and needs are very great, such decisions are exceptionally difficult. In these settings, economic evaluation can be particularly useful in determining how to best improve health and welfare. Typically, cost-effectiveness analysis (CEA) is used to prioritize interventions within the health care sector. This approach…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Global | Policy/Regulation | Priority Setting/Ethics | Costing Methods | Health Outcomes -
Working PaperPublication 2018Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis
Increasing life expectancy is a major goal of many policies implemented around the world. As …
Increasing life expectancy is a major goal of many policies implemented around the world. As a result, the value of reducing mortality risk has been extensively studied and several organizations have developed recommendations for estimating these values in benefit-cost analysis. However, both the recommendations and the underlying research primarily address high-income settings, raising questions about the extent to which the results are applicable in low- and middle-income countries. The recommendations are also diverse, reflecting differing…
Benefit-Cost Analysis | Decision Analysis | Global | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Health Outcomes | Social Determinants | Economics/Finance | Health/Medicine -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Benefit-Cost Analysis | Decision Analysis | Global | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Health Outcomes | Social Determinants | Economics/Finance | Health/Medicine | Critical Thinking/Analysis -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Mathematical Models | Cost-Effectiveness Analysis | Global | Policy/Regulation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Technology Assessment | Global | Policy/Regulation | Probability/Bayes | Test Performance | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | North America -
ReviewPublication 2018Patient Variability Seldom Assessed in Cost-Effectiveness Studies
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether …
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether each cost-effectiveness analysis (CEA) study reported subgroup results and collected data on the defining characteristics of these subgroups. Since estimates can vary across patient subgroups when characteristics are influenced by preferences, outcome risks, treatment effectiveness, life expectancy, or associated costs it can be important to track and report these differences. The authors identified whether any of the CEA subgroup results…
Cost-Effectiveness Analysis | Global | Policy/Regulation | Preferences/Values | Social Determinants | Health Systems | Health/Medicine